Research graph
References from Cardio-immuno-oncology in cardiac tumors and cardiac metastases: immune microenvironment, therapeutic opportunities, and cardiotoxicity. Local targets link to admitted publications; unresolved targets remain external evidence.
Cardiac tumors: Jacc cardiooncology state-of-the-art review
10.1016/j.jaccao.2020.05.009 · 2020 · External reference
Clinical features and prognosis of cardiac metastatic tumors
10.1186/s12885-023-11733-1 · 2023 · External reference
Cardiac tumours: Diagnosis and management
10.1016/s1470-2045(05)70093-0 · 2005 · External reference
Primary cardiac tumors
2011 · External reference
Primary tumors of the heart
10.1097/hco.0000000000000335 · 2016 · External reference
Sarcoma: Cardiovascular and oncologic considerations: Jacc: Cardiooncology state-of-the-art review
10.1016/j.jaccao.2025.09.005 · 2025 · External reference
The immune contexture in human tumours: Impact on clinical outcome
10.1038/nrc3245 · 2012 · External reference
Understanding the tumor immune microenvironment (Time) for effective therapy
10.1038/s41591-018-0014-x · 2018 · External reference
Investigating intra-tumoural heterogeneity and microenvironment diversity in primary cardiac angiosarcoma through single-cell rna sequencing
10.1002/ctm2.70113 · 2024 · External reference
Resolving the heterogeneous tumour microenvironment in cardiac myxoma through single-cell and spatial transcriptomics
10.1002/ctm2.1581 · 2024 · External reference
Multi-omics data reveal the origin of cardiac myxoma
10.1038/s42003-025-08752-y · 2025 · External reference
Single-cell rna sequencing and proteomics uncover sirpα-cd47 immune checkpoint and glycolysis-driven immune evasion in cardiac myxoma
10.3389/fimmu.2025.1652645 · 2025 · External reference
Innate immunity in cardiac myxomas and its pathological and clinical correlations
10.1177/1753425917741678 · 2018 · External reference
Autocrine regulation of interleukin-6 via the activation of stat3 and akt in cardiac myxoma cells
10.3390/ijms25042232 · 2024 · External reference
Autophagy in cardiac myxoma: An important puzzle piece in understanding its inflammatory environment
10.1016/j.prp.2021.153609 · 2021 · External reference
Radiotherapy combined with anti-pd-1 and tki for primary cardiac angiosarcoma considering the joint assessment of tlss and pd-l1: A case report
10.1186/s13019-024-02752-5 · 2024 · External reference
Clinical outcomes among immunotherapy-treated patients with primary cardiac soft tissue sarcomas: A multicenter retrospective study
10.1016/j.jaccao.2023.11.007 · 2024 · External reference
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: A multicenter international retrospective study
10.1136/jitc-2024-009364 · 2025 · External reference
Management and prognosis of cardiac metastatic merkel cell carcinoma: A case-control study and literature review
10.3390/cancers14235914 · 2022 · External reference
Myocarditis in patients treated with immune checkpoint inhibitors
10.1016/j.jacc.2018.02.037 · 2018 · External reference
Cardiovascular toxicities associated with immune checkpoint inhibitors
10.1093/cvr/cvz026 · 2019 · External reference
2022 esc guidelines on cardio-oncology developed in collaboration with the european hematology association (Eha), the european society for therapeutic radiology and oncology (Estro) and the international cardio-oncology society (Ic-Os)
10.1093/eurheartj/ehac244 · 2022 · External reference
Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study
10.1016/s1470-2045(18)30608-9 · 2018 · External reference
Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases
10.1097/00005792-200105000-00002 · 2001 · External reference
Anti-pd-1 therapy-a potential treatment for myocardial metastasis from nasopharyngeal carcinoma: A case report
10.3389/fimmu.2021.688682 · 2021 · External reference
The tumor microenvironment may trigger lymphoproliferation in cardiac myxoma
10.1016/j.tranon.2020.100911 · 2021 · External reference
The sarcoma immune landscape: Emerging challenges, prognostic significance and prospective impact for immunotherapy approaches
10.3390/cancers13030363 · 2021 · External reference
Tumour-associated macrophages as treatment targets in oncology
10.1038/nrclinonc.2016.217 · 2017 · External reference
Macrophage diversity enhances tumor progression and metastasis
10.1016/j.cell.2010.03.014 · 2010 · External reference
B cells are associated with survival and immunotherapy response in sarcoma
10.1038/s41586-019-1906-8 · 2020 · External reference
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (Sarc028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial
10.1016/s1470-2045(17)30624-1 · 2017 · External reference
The blockade of immune checkpoints in cancer immunotherapy
10.1038/nrc3239 · 2012 · External reference
Immune checkpoint blockade: A common denominator approach to cancer therapy
10.1016/j.ccell.2015.03.001 · 2015 · External reference
Pd-1 blockade induces responses by inhibiting adaptive immune resistance
10.1038/nature13954 · 2014 · External reference
The emerging hallmarks of cancer metabolism
10.1016/j.cmet.2015.12.006 · 2016 · External reference
Metabolic instruction of immunity
10.1016/j.cell.2017.04.004 · 2017 · External reference
Immunity, inflammation, and cancer
10.1016/j.cell.2010.01.025 · 2010 · External reference
Cytokines in cancer pathogenesis and cancer therapy
10.1038/nrc1252 · 2004 · External reference
Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges
10.1038/nrclinonc.2018.29 · 2018 · External reference
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
10.1038/nrc.2016.36 · 2016 · External reference
Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia
10.1038/s41569-020-0348-1 · 2020 · External reference
Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: The paradigm of radiotherapy
10.1016/j.pharmthera.2024.108670 · 2024 · External reference
Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis
10.1158/2159-8290.cd-22-1180 · 2023 · External reference
Revealing the crucial roles of suppressive immune microenvironment in cardiac myxoma progression
10.1038/s41392-024-01912-2 · 2024 · External reference
Resolving the heterogeneous tumour microenvironment in cardiac myxoma through single-cell and spatial transcriptomics
10.1002/ctm2.1581 · ExternalCitation · doi-reference
Investigating intra-tumoural heterogeneity and microenvironment diversity in primary cardiac angiosarcoma through single-cell rna sequencing
10.1002/ctm2.70113 · ExternalCitation · doi-reference
Immune checkpoint blockade: A common denominator approach to cancer therapy
10.1016/j.ccell.2015.03.001 · ExternalCitation · doi-reference
Immunity, inflammation, and cancer
10.1016/j.cell.2010.01.025 · ExternalCitation · doi-reference
Macrophage diversity enhances tumor progression and metastasis
10.1016/j.cell.2010.03.014 · ExternalCitation · doi-reference
Metabolic instruction of immunity
10.1016/j.cell.2017.04.004 · ExternalCitation · doi-reference
The emerging hallmarks of cancer metabolism
10.1016/j.cmet.2015.12.006 · ExternalCitation · doi-reference
Myocarditis in patients treated with immune checkpoint inhibitors
10.1016/j.jacc.2018.02.037 · ExternalCitation · doi-reference
Cardiac tumors: Jacc cardiooncology state-of-the-art review
10.1016/j.jaccao.2020.05.009 · ExternalCitation · doi-reference
Clinical outcomes among immunotherapy-treated patients with primary cardiac soft tissue sarcomas: A multicenter retrospective study
10.1016/j.jaccao.2023.11.007 · ExternalCitation · doi-reference
Sarcoma: Cardiovascular and oncologic considerations: Jacc: Cardiooncology state-of-the-art review
10.1016/j.jaccao.2025.09.005 · ExternalCitation · doi-reference
Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: The paradigm of radiotherapy
10.1016/j.pharmthera.2024.108670 · ExternalCitation · doi-reference
Autophagy in cardiac myxoma: An important puzzle piece in understanding its inflammatory environment
10.1016/j.prp.2021.153609 · ExternalCitation · doi-reference
The tumor microenvironment may trigger lymphoproliferation in cardiac myxoma
10.1016/j.tranon.2020.100911 · ExternalCitation · doi-reference
Cardiac tumours: Diagnosis and management
10.1016/s1470-2045(05)70093-0 · ExternalCitation · doi-reference
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (Sarc028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial
10.1016/s1470-2045(17)30624-1 · ExternalCitation · doi-reference
Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study
10.1016/s1470-2045(18)30608-9 · ExternalCitation · doi-reference
Pd-1 blockade induces responses by inhibiting adaptive immune resistance
10.1038/nature13954 · ExternalCitation · doi-reference
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
10.1038/nrc.2016.36 · ExternalCitation · doi-reference
Cytokines in cancer pathogenesis and cancer therapy
10.1038/nrc1252 · ExternalCitation · doi-reference
The blockade of immune checkpoints in cancer immunotherapy
10.1038/nrc3239 · ExternalCitation · doi-reference
The immune contexture in human tumours: Impact on clinical outcome
10.1038/nrc3245 · ExternalCitation · doi-reference
Tumour-associated macrophages as treatment targets in oncology
10.1038/nrclinonc.2016.217 · ExternalCitation · doi-reference
Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges
10.1038/nrclinonc.2018.29 · ExternalCitation · doi-reference
Revealing the crucial roles of suppressive immune microenvironment in cardiac myxoma progression
10.1038/s41392-024-01912-2 · ExternalCitation · doi-reference
Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia
10.1038/s41569-020-0348-1 · ExternalCitation · doi-reference
B cells are associated with survival and immunotherapy response in sarcoma
10.1038/s41586-019-1906-8 · ExternalCitation · doi-reference
Understanding the tumor immune microenvironment (Time) for effective therapy
10.1038/s41591-018-0014-x · ExternalCitation · doi-reference
Multi-omics data reveal the origin of cardiac myxoma
10.1038/s42003-025-08752-y · ExternalCitation · doi-reference
Cardiovascular toxicities associated with immune checkpoint inhibitors
10.1093/cvr/cvz026 · ExternalCitation · doi-reference
2022 esc guidelines on cardio-oncology developed in collaboration with the european hematology association (Eha), the european society for therapeutic radiology and oncology (Estro) and the international cardio-oncology society (Ic-Os)
10.1093/eurheartj/ehac244 · ExternalCitation · doi-reference
Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases
10.1097/00005792-200105000-00002 · ExternalCitation · doi-reference
Primary tumors of the heart
10.1097/hco.0000000000000335 · ExternalCitation · doi-reference
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: A multicenter international retrospective study
10.1136/jitc-2024-009364 · ExternalCitation · doi-reference
Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis
10.1158/2159-8290.cd-22-1180 · ExternalCitation · doi-reference
Innate immunity in cardiac myxomas and its pathological and clinical correlations
10.1177/1753425917741678 · ExternalCitation · doi-reference
Clinical features and prognosis of cardiac metastatic tumors
10.1186/s12885-023-11733-1 · ExternalCitation · doi-reference
Radiotherapy combined with anti-pd-1 and tki for primary cardiac angiosarcoma considering the joint assessment of tlss and pd-l1: A case report
10.1186/s13019-024-02752-5 · ExternalCitation · doi-reference
Anti-pd-1 therapy-a potential treatment for myocardial metastasis from nasopharyngeal carcinoma: A case report
10.3389/fimmu.2021.688682 · ExternalCitation · doi-reference
Single-cell rna sequencing and proteomics uncover sirpα-cd47 immune checkpoint and glycolysis-driven immune evasion in cardiac myxoma
10.3389/fimmu.2025.1652645 · ExternalCitation · doi-reference
The sarcoma immune landscape: Emerging challenges, prognostic significance and prospective impact for immunotherapy approaches
10.3390/cancers13030363 · ExternalCitation · doi-reference
Management and prognosis of cardiac metastatic merkel cell carcinoma: A case-control study and literature review
10.3390/cancers14235914 · ExternalCitation · doi-reference
Autocrine regulation of interleukin-6 via the activation of stat3 and akt in cardiac myxoma cells
10.3390/ijms25042232 · ExternalCitation · doi-reference
